Cargando…

Perceptions and Experiences of Atrial Fibrillation Patients on Their Condition and Oral Anticoagulant Treatment

INTRODUCTION: This study was designed to gain insight into the treatment experiences and expectations of patients with atrial fibrillation (AF) who were treated with vitamin K antagonists (VKA) or recently switched from VKA treatment to direct oral anticoagulant (DOAC) therapy. Little is known about...

Descripción completa

Detalles Bibliográficos
Autores principales: Slavenburg, Marcel, van den Bent, Janneke H., Barten, Thierry, Reijs-Scheijgrond, Margje, de Koning, Constance
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584713/
https://www.ncbi.nlm.nih.gov/pubmed/32462633
http://dx.doi.org/10.1007/s40119-020-00173-8
Descripción
Sumario:INTRODUCTION: This study was designed to gain insight into the treatment experiences and expectations of patients with atrial fibrillation (AF) who were treated with vitamin K antagonists (VKA) or recently switched from VKA treatment to direct oral anticoagulant (DOAC) therapy. Little is known about the perceptions and expectations of patients with AF who are being prescribed oral anticoagulants (OACs), leading to different expectations of patient and doctor of their respective roles in disease management between the doctor [general practitioner (GP) or cardiologist] and patient on their respective roles in disease management. METHODS: A market research study was conducted consisting of two phases: (1) qualitative research (n = 16) in which in-depth interviews were conducted; and (2) quantitative research (n = 101), using a conjoint analysis. RESULTS: Patients reported that the three most important aspects of OAC treatment were (in order of priority) reduced risk of blood clots/stroke, low bleeding risk, and not having to use a thrombosis service. Only 12% of VKA-treated patients were familiar with DOAC, although 52% were open to switching when presented with a DOAC profile. CONCLUSIONS: GPs and patients are waiting for the other to mention issues surrounding AF treatment such as switching, use of thrombosis service, and number of pills to take first. The perceptions and experiences of patients with AF regarding their disease and treatment highly influence the decisions GPs make, together with these patients, as well as considerations that patients have regarding their treatment; GPs need to be aware of their AF patients’ perceptions and experiences with their condition and medication’ in order to facilitate discussions with patients and improve clinical outcomes.